Survival of ovarian cancer patients in Denmark: excess mortality risk analysis of five-year relative survival in the period 1978-2002 - PubMed (original) (raw)
Survival of ovarian cancer patients in Denmark: excess mortality risk analysis of five-year relative survival in the period 1978-2002
Charlotte Gerd Hannibal et al. Acta Obstet Gynecol Scand. 2008.
Free article
Abstract
Objective: To explore the variation in ovarian cancer survival in Denmark in the period 1978-2002 in relation to time since diagnosis, age at diagnosis, period of diagnosis, stage and histology.
Design: Register-based cohort study.
Setting: Denmark in the period 1978-2002.
Population: Using the nationwide Danish Cancer Registry, we included a total of 13,035 women diagnosed with invasive ovarian cancer in Denmark in the period 1978-2002.
Methods: Excess mortality risk analyses of five-year relative survival of ovarian cancer patients diagnosed in the period 1978-2002 with follow-up through 2006 were made based on data from the NORDCAN database.
Main outcome measures: Five-year relative survival, excess mortality rate (ER) and relative excess mortality risk (RER) after an ovarian cancer diagnosis.
Results: The relative survival of Danish ovarian cancer patients slightly increased in the period 1978-2002. The ERs were highest in the first year following diagnosis, in particular in the first three months, and among older patients, even for localized and regional tumors. The pattern remained the same when stratified by histological subgroup. Older age at diagnosis, earlier period of diagnosis, more advanced stage at diagnosis and being diagnosed with undifferentiated carcinoma predicted poorer survival among Danish ovarian cancer patients diagnosed in the period 1978-2002.
Conclusions: The survival of Danish ovarian cancer patients has slightly increased from 1978 through 2002. Despite this, the mortality rate of ovarian cancer in Denmark is still higher than in the other Nordic countries. Explanations for these differences are still to be identified.
Similar articles
- Trends in the incidence and mortality of ovarian cancer in Denmark 1978-2002. Comparison with other Nordic countries.
Kjaerbye-Thygesen A, Huusom LD, Frederiksen K, Kjaer SK. Kjaerbye-Thygesen A, et al. Acta Obstet Gynecol Scand. 2005 Oct;84(10):1006-12. doi: 10.1111/j.0001-6349.2005.00878.x. Acta Obstet Gynecol Scand. 2005. PMID: 16167920 - Trends in the survival of patients diagnosed with breast cancer in the Nordic countries 1964-2003 followed up to the end of 2006.
Tryggvadóttir L, Gislum M, Bray F, Klint A, Hakulinen T, Storm HH, Engholm G. Tryggvadóttir L, et al. Acta Oncol. 2010 Jun;49(5):624-31. doi: 10.3109/02841860903575323. Acta Oncol. 2010. PMID: 20429724 - Trends in the survival of patients diagnosed with kidney or urinary bladder cancer in the Nordic countries 1964-2003 followed up to the end of 2006.
Engholm G, Hakulinen T, Gislum M, Tryggvadóttir L, Klint A, Bray F, Storm HH. Engholm G, et al. Acta Oncol. 2010 Jun;49(5):655-64. doi: 10.3109/02841860903575299. Acta Oncol. 2010. PMID: 20156116 - Occupational cancer in Denmark. Cancer incidence in the 1970 census population.
Lynge E, Thygesen L. Lynge E, et al. Scand J Work Environ Health. 1990;16 Suppl 2:3-35. Scand J Work Environ Health. 1990. PMID: 2237334 Review.
Cited by
- Role of CA125 in predicting ovarian cancer survival - a review of the epidemiological literature.
Gupta D, Lis CG. Gupta D, et al. J Ovarian Res. 2009 Oct 9;2:13. doi: 10.1186/1757-2215-2-13. J Ovarian Res. 2009. PMID: 19818123 Free PMC article. - An outlook on ovarian cancer and borderline ovarian tumors: focus on genomic and proteomic findings.
Tinelli A, Vergara D, Martignago R, Leo G, Pisanò M, Malvasi A. Tinelli A, et al. Curr Genomics. 2009 Jun;10(4):240-9. doi: 10.2174/138920209788488553. Curr Genomics. 2009. PMID: 19949545 Free PMC article. - Predictors of mortality within 1 year after primary ovarian cancer surgery: a nationwide cohort study.
Ørskov M, Iachina M, Guldberg R, Mogensen O, Mertz Nørgård B. Ørskov M, et al. BMJ Open. 2016 Apr 21;6(4):e010123. doi: 10.1136/bmjopen-2015-010123. BMJ Open. 2016. PMID: 27103625 Free PMC article. - MiR-23b targets cyclin G1 and suppresses ovarian cancer tumorigenesis and progression.
Yan J, Jiang JY, Meng XN, Xiu YL, Zong ZH. Yan J, et al. J Exp Clin Cancer Res. 2016 Feb 13;35:31. doi: 10.1186/s13046-016-0307-1. J Exp Clin Cancer Res. 2016. PMID: 26872615 Free PMC article. - Exosomal miR-34b inhibits proliferation and the epithelial-mesenchymal transition by targeting Notch2 in ovarian cancer.
Lu S, Liu W, Shi H, Zhou H. Lu S, et al. Oncol Lett. 2020 Sep;20(3):2721-2728. doi: 10.3892/ol.2020.11837. Epub 2020 Jul 9. Oncol Lett. 2020. PMID: 32782588 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical